Indian API production takes hit as APPCB shuts 12 plants

By Natalie Morrison

- Last updated on GMT

API manufacturing for drugs in India: APPCB

Related tags: Pharmaceutical drug, Pharmacology

API production in India will take a hit this week with plant closures for Aurobindo, Hetero Drugs, Divis Pharmaceuticals, and Sri Krishna Pharmaceuticals following allegations of environmental wrongdoing.

In a crackdown on drugsmakers failing to abide by the 1974 Water (Prevention & Control of Pollution) Act, the Andhra Pradesh Pollution Control Board (APPCB) will force the closure of 12 plants in the area by July 23.

As part of the swoop, bulk manufacturer Aurobindo will close it’s API (active pharmaceutical ingredient) plants Unit-IX and Unit-I, Hetero will end production at three facilities, whilst Divis and Sri Krishna will each close one factory.

Cirex Pharmaceuticals, Covalent Laboratories, Innogent Laboratories and SMS Pharma will also cease production at some of their plants.

“After detailed discussions, the board is of the firm opinion that certain industries are violating the orders of the Supreme Court of India and the ban notification issued by the Andhra Pradesh government, among others,”​ APPCB said in a statement.

The news follows APPCB’s stricter policies for local drug producers last year, after it reportedly suspected several plants of disposing chemicals unsafely.

Around the same time Aurobindo was issued with an FDA (US Food and Drug Administration) warning letter for two of its plants regarding cGMP (current good manufacturing practices), one specifically warning about discrepancies in the environmental monitoring data it presented from 2009 – 2010.

Fighting back

The firms are now reportedly now set to bring the case to India’s Appellate Tribunal on Wednesday.

During the appeal, it is said the firms will negotiate a deal which will allow them to work again, and will promise to adhere to the organisation’s rules from now on.

In a statement, SMS Pharma said they will “take the necessary steps to revoke the closure orders through the respective authorities shortly.”

Related news

Show more

Related products

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us

Products

View more

Webinars